Suppression of myoclonus in SCA2 by piracetam.
We report on a 30-year-old patient with advanced cerebellar degeneration due to SCA2. He presented with severe myoclonus, which was resistant to conventional therapy and dramatically improved after administration of 12-18 gm/die piracetam. Piracetam may be considered in the treatment of refractory myoclonus in spinocerebellar degenerations.
De Rosa
Anna
A
Department of Neurological Sciences, Federico II University, Naples, Italy.
Striano
Pasquale
P
Barbieri
Fabrizio
F
de Falco
Arturo
A
Rinaldi
Carlo
C
Tucci
Tecla
T
Striano
Salvatore
S
Filla
Alessandro
A
De Michele
Giuseppe
G
D000328:Adult; D001259:Ataxia / Q000188:drug therapy* / Q000235:genetics; D000067528:Ataxins; D004305:Dose-Response Relationship, Drug; D020234:Gait Ataxia / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D009207:Myoclonus / Q000188:drug therapy* / Q000235:genetics; D009419:Nerve Tissue Proteins / Q000235:genetics*; D009460:Neurologic Examination / Q000187:drug effects; D010889:Piracetam / Q000009:adverse effects / Q000627:therapeutic use*; D012008:Recurrence; D020754:Spinocerebellar Ataxias / Q000188:drug therapy* / Q000235:genetics; D013375:Substance Withdrawal Syndrome / Q000175:diagnosis; D016896:Treatment Outcome; D018911:Trinucleotide Repeats / Q000235:genetics
D000067528:Ataxins; D009419:Nerve Tissue Proteins; D010889:Piracetam